Corcept Therapeutics Incorporated CORT recently announced the submission of a new drug application (NDA) to the FDA for its ...

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body ...

Agents that directly lower ACTH secretion by a pituitary adenoma represent an attractive option for the treatment of Cushing's disease, as these drugs directly target the pathogenesis of disease.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Korlym became the first drug approved by the FDA to treat Cushing syndrome in 2012. It wasn’t until recently, however, that researchers discovered that hypercortisolism, previously believed to ...

The drug has received orphan drug designation in the United States and the European Union for the treatment of Cushing's syndrome. Cushing's syndrome is a condition characterized by excessive ...

Also Read: Corcept Therapeutics’ Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast CATALYST is a prospective Phase 4 study with two parts.

radiotherapy or drug therapy. While medical therapy for Cushing's syndrome has been limited, several new agents are being investigated. This aim of this review is to analyze and present the ...